Dermata Therapeutics (DRMA) announced that the last patient has completed their last visit in the company’s first pivotal Phase 3 Spongilla Treatment for Acne Research trial of Xingari, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The company remains on track to announce topline data by the end of March 2025. If positive, the results the Phase 3 program would be used to support the filing of a new drug application with the FDA.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRMA:
- Dermata Therapeutics receives notice of acceptance for Australian patent
- APO accepts Dermata’s patent application for DMT410 program for hyperhidrosis
- Dermata Therapeutics files to sell 1.94M shares of common stock for holders
- Biotech Alert: Searches spiking for these stocks today
- Dermata Therapeutics to prices 2M shares at $1.27 in private placement